logo-loader
viewTissue Regenix Group PLC

Tissue Regenix MD says the company is at an "exciting period"

Antony Odell, MD of Tissue Regenix (LON:TRX), explains to Proactiveinvestors that the company is at an "exciting period" in its development and, because it is a medical devices company, it is a "lower risk, lower cost and more predictable" business model than a biotech business. Antony also explains that the real benefits of the TRX patented technology are the opportunities from "big unmet needs" in the aging population.

Quick facts: Tissue Regenix Group PLC

Price: 3 GBX

AIM:TRX
Market: AIM
Market Cap: £35.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Holding(s) in Company

1 hour, 20 minutes ago

Trading Update

10 hours, 47 minutes ago

Holding(s) in Company

2 days, 2 hours ago

Appointment of CFO

on 08/28/2019

Directorate Change

on 08/01/2019

2 min read